Revenue
2022
2023
2024
2025
Tectonic Therapeutic, Inc. (TECX)
Price$23.29Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — |
| Research & development | $63.5M | $41.4M | $37.0M | $72.2M | $83.1M | $87.2M | $55.0M | $35.1M | $15.2M |
| Operating expenses | $84.0M | $58.0M | $44.6M | $105.4M | $118.8M | $120.2M | $75.8M | $46.2M | $18.4M |
| Operating income | −$84.0M | −$58.0M | −$44.6M | −$105.4M | −$118.8M | −$120.2M | −$75.8M | −$46.2M | −$18.4M |
| EBITDA | −$82.7M | −$56.4M | −$43.2M | −$104.0M | −$117.4M | −$119.0M | −$75.0M | −$45.9M | −$18.3M |
| Net income | −$74.2M | −$58.0M | −$42.8M | −$105.9M | −$119.1M | −$119.7M | −$73.0M | −$46.4M | −$18.6M |
| Basic EPSper basic share | -$4.05 | -$6.83 | -$33.76 | -$77.62 | -$89.17 | -$106.17 | -$85.32 | -$116.11 | -$268.79 |
| Diluted EPSper diluted share | -$4.05 | -$6.83 | -$33.76 | -$77.62 | -$89.17 | -$106.17 | -$85.32 | -$116.11 | -$268.79 |
Owners
Reported shareholders
≈31.32%of listed shares
SPRINGER TIMOTHY A6.02M shares · Apr 11, 2025
View holders
| Holder | % owned |
|---|---|
SPRINGER TIMOTHY A | ≈31.32%6.02M shares |
FMR LLC | 14.71%2.83M shares |
TCG Crossover Management, LLC | 6.26%1.2M shares |
Aberdeen Group plc | 5.94%1.14M shares |
BlackRock, Inc. | 4.48%862.59K shares |
First Light Asset Management, LLC | 4.16%800.73K shares |
MCGUIRE TERRANCE | ≈3.42%657.98K shares |
BAKER BROS. ADVISORS LP | 3.16%607.79K shares |
5AM Venture Management, LLC | 3.15%606.66K shares |
BRAIDWELL LP | 3.10%596.9K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.54%488.81K shares |
REICIN ALISE | ≈2.28%437.65K shares |
Vestal Point Capital, LP | 2.21%425K shares |
Bollard Group LLC | 1.57%302.95K shares |
KENNEDY CAPITAL MANAGEMENT LLC | 1.47%282.2K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.41%270.46K shares |
ORBIMED ADVISORS LLC | 1.18%226.6K shares |
STATE STREET CORP | 1.14%219.91K shares |
Ikarian Capital, LLC | 1.07%205.84K shares |
D. E. Shaw & Co., Inc. | 0.97%186.55K shares |
Percentages use 19.24M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 4, 2026Form 4 · 10b5-1 | Ruddy Marcella K.Chief Medical Officer | SellCommon Stock | 1.1K | $30.00 | $31.9K | 67.7K |
| Apr 1, 2026Form 4 · 10b5-1 | Ruddy Marcella K.Chief Medical Officer | SellCommon Stock | 1.0K | $31.05 | $31.1K | 68.7K |
| Mar 6, 2026Form 4 · 10b5-1 | Ruddy Marcella K.Chief Medical Officer | SellCommon Stock | 10.0K | $30.00 | $300.0K | 69.7K |
| Mar 6, 2026Form 4 · 10b5-1 | McNamara PeterChief Scientific Officer | SellCommon Stock | 215 | $35.00 | $7.5K | 55.3K |
| Mar 6, 2026Form 4 · 10b5-1 | McNamara PeterChief Scientific Officer | SellCommon Stock | 6.0K | $30.00 | $181.4K | 55.5K |
Community posts
Tectonic reports early safety data for vascular-disease antibody
Tectonic Therapeutic ($TECX) reported favorable Phase Ia safety findings for TX2100, an experimental antibody being developed for hereditary hemorrhagic telangiectasia, an inherited vascular disorder. Across six single-dose cohorts in healt ...
